Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Wave Life Sciences (WVE) EBITDA Margin (2016 - 2025)

Wave Life Sciences' EBITDA Margin history spans 11 years, with the latest figure at 579.68% for Q2 2025.

  • For Q2 2025, EBITDA Margin fell 41207.0% year-over-year to 579.68%; the TTM value through Dec 2025 reached 1143.37%, down 110145.0%, while the annual FY2025 figure was 478.31%, 38861.0% down from the prior year.
  • EBITDA Margin reached 579.68% in Q2 2025 per WVE's latest filing, down from 510.3% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 14.67% in Q3 2023 to a low of 13712.28% in Q3 2022.
  • Average EBITDA Margin over 5 years is 1890.09%, with a median of 189.86% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: plummeted -1369515bps in 2022, then surged 1372695bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 44.75% in 2021, then dropped by -20bps to 53.71% in 2022, then soared by 76bps to 12.63% in 2023, then skyrocketed by 216bps to 14.61% in 2024, then crashed by -4067bps to 579.68% in 2025.
  • Per Business Quant, the three most recent readings for WVE's EBITDA Margin are 579.68% (Q2 2025), 510.3% (Q1 2025), and 14.61% (Q4 2024).